Can IL-1 be used as a target for osteoarthritis?
Abstract
We read with deep interest the article by Kloppenburg et al ,1 which was aimed at assessing the efficacy, safety, pharmacokinetics and pharmacodynamics of anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). The results indicated that administration of 200 mg lutikizumab subcutaneously every 2 weeks for 24 weeks did not improve pain or imaging outcomes in erosive HOA compared...
Paper Details
Title
Can IL-1 be used as a target for osteoarthritis?
Published Date
Apr 30, 2019
Volume
79
Issue
7
Pages
e88 - e88
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History